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Unraveling the Mechanistic Basis of
Mesenchymal Stem Cell Activity in the Heart
Heart failure affects millions of Americans each year. Although many diverse factors cancontribute to its etiology, cardiomyocyte loss is frequently involved. Most studies indi-
cate that the ability of the myocardium to regenerate in the setting of heart disease is lim-
ited; consequently cardiomyocyte loss is cumulative and if unchecked will ultimately lead
to organ failure. Interventions aimed at blocking or reducing cardiomyocyte death in
response to acute or chronic insult are thus of considerable therapeutic value. In addition,
several strategies to augment cardiomyocyte number have been proposed, including induc-
tion of cardiomyocyte cell cycle activity as well as transplantation of cardiomyocytes or car-
diomyogenic stem cells. These latter strategies are based on the notion that increasing car-
diomyocyte number in diseased hearts will result in a concomitant increase in cardiac func-
tion, provided that the nascent cells participate in a functional syncytium with the rest of
the heart.  
Mesenchymal stem cell (MSC) transplantation has been extensively studied in the set-
ting of experimental myocardial injury [1,2]. Although many studies demonstrated that
MSC transplantation enhanced cardiac function in animals with experimental infarcts, the
mechanistic basis for functional improvement was somewhat controversial. Several recent
reports have significantly clarified the situation. An important breakthrough came from the
Dzau laboratory in 2003. These investigators demonstrated that, when transplanted into
rat hearts following permanent coronary artery occlusion, MSCs expressing a transgene
encoding Akt (a serine threonine kinase with potent pro-survival activity) exhibited greater
retention as compared to MSCs lacking the transgene [3]. Mice with Akt-expressing MSCs
exhibited a dramatic reduction in acute infarct size and acute cardiomyocyte apoptosis, as
well as an increase in cardiac function at two weeks post-injury. Interestingly, MSCs lack-
ing the Akt transgene also had a beneficial impact, but to a lesser degree. Immune histol-
ogy suggested cardiomyogenic differentiation of the MSCs. In subsequent studies [4,5],
Dzau and colleagues demonstrated that conditioned medium prepared from Akt-expressing
MSCs cultured under hypoxic conditions essentially replicated the results observed with
MSC transplantation. These data suggested that the MSCs acted through a paracrine mech-
anism, and questioned the relevance of the apparent cardiomyogenic differentiation
reported in previous studies.
The most recent installment of this series, which appears in this issue of Molecular
Therapy [6], further examined cardiomyogenic differentiation of transplanted MSCs. In this
study, Noiseux and colleagues injected MSCs expressing EGFP, Cre recombinase and Akt
into the hearts of R26R mice following permanent coronary artery occlusion. R26R mice
harbor a Cre-dependent β-galactosidase reporter in the ubiquitously-expressed Rosa26
locus. In this system, EGFP activity can be used to track donor-cell survival, and induction
of β-galactosidase activity can be used to track fusion events between donor and host cells.
Donor MSCs were readily detected at 3 and 7 days following transplantation, but were only
infrequently observed by 14 days post-injury. The vast majority of donor cells did not
exhibit a cardiomyocyte phenotype (based on colocalization of EGFP and α-sarcomeric
actin immune reactivity). However, a small number of donor-derived cells exhibited a car-
diomyocyte-like morphology (only nine cells were detected in over 600 tissue sections
examined); these cells also exhibited β-galactosidase activity, indicating that they arose
from MSC-cardiomyocyte fusion events. A single cell with EGFP and α-sarcomeric actin
immune reactivity, but lacking β-galactosidase activity, was observed. Although this cell
may have arisen as a consequence of cardiomyogenic differentiation, it could also have rep-
resented a false-positive event if the penetrance of the R26R reporter was less than 100%.
Other analyses suggested that fusion events also occurred between the donor MSCs and
non-cardiomyocytes.
Collectively, these studies provide considerable insight as to how MSC transplantation
impacts function in injured hearts. Clearly, the benefit of MSC transplantation in injured
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hearts resides in their ability to secrete cardioprotective paracrine factors in the myocardi-
um, and is independent of their differentiation into cardiomyocytes. Moreover, a hypox-
ic environment appears to enhance the production of MSC-derived cardioprotective fac-
tors. This latter finding might underlie the observation that acute myocardial infarction
patients with more severe cardiac dysfunction (and, presumably, a larger ischemic bur-
den) exhibit the greatest benefit from intracoronary infusion of marrow-derived cells [7].
Although enhancement of short-term MSC survival (via Akt expression) increases their
cardioprotective activity in experimental animals, long-term MSC persistence is not
required for a long-term impact on cardiac function. Similarly, improvement in cardiac
function following intra-coronary bone marrow cell infusion in patients with acute
myocardial infarction persists for 18 months [8]. However, the observation that cardiac
function in patients not receiving intra-coronary infusions “catches up” to that seen in
the treated patients makes it difficult to compare the experimental and clinical studies.
While one can easily envision how the transient presence of MSCs could have a long-
term impact in the setting of reperfusion injury, it is intriguing that the current study
demonstrated a long term impact in the setting of permanent coronary artery occlusion
(as opposed to reperfusion injury), particularly given the absence of enhanced peri-infarct
vessel density in hearts receiving MSCs vs. controls [5, 9-11]. The mechanistic basis for
the sustained enhancement of cardiac function is not fully understood. It may result from
the salvage of at-risk cardiomyocytes at the infarct border zone; indeed, previous studies
have shown a critical relationship between infarct size and the propensity to progress to
heart failure in rats [12]. Alternatively, MSC transplantation may result in more favorable
post-infarction remodeling, which in turn may contribute to the sustained impact on car-
diac function.  It has recently been shown that MSC transplantation results in enhanced
cellularity in the infarct scar, which is accompanied by improved tissue elasticity [9].
These characteristics would likely result in increased myocardial compliance as well as
reduced scar expansion at the infarct border zone. A similar mechanism likely contributes
to the improved cardiac function observed following transplantation of other cell types
in injured hearts [13]. 
Although we are beginning to understand the mechanistic basis for MSC-based car-
dioprotection, many questions remain.  Additional experiments to more thoroughly
characterize post-injury remodeling are required to further clarify the mechanisms by
which exogenous MSC transplantation enhance cardiac function in injured hearts.
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